Cargando…

A. V. M. A.

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	1901
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9337459/ https://www.ncbi.nlm.nih.gov/pubmed/36392693

Ejemplares similares

A. V. M. A. Committee on Diseases
por: Ranck, E. M., et al.
Publicado: (1901)

Section Work in the U.S.V.M.A.
por: Dalrymple, W. H.
Publicado: (1897)

Optimism v. Pessimism in I.M.S.
Publicado: (1913)

Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine
por: Zeng, Guangting
Publicado: (2022)

New-onset MOGAD after first-dose SARS-CoV-2 mRNA vaccination with relapse following SARS-CoV-2 mRNA booster
por: Arismendez, Alan A., et al.
Publicado: (2023)

Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine
por: Bradley, Todd, et al.
Publicado: (2021)

The B. M. A. and the I. M. S.
por: Buchanan, W. J.
Publicado: (1921)

Sunitinib reduces the infection of SARS-CoV, MERS-CoV and SARS-CoV-2 partially by inhibiting AP2M1 phosphorylation
por: Wang, Pei-Gang, et al.
Publicado: (2020)

Effectiveness of the mRNA-1273 Vaccine during a SARS-CoV-2 Delta Outbreak in a Prison
por: Chin, Elizabeth T., et al.
Publicado: (2021)

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
por: Widge, Alicia T., et al.
Publicado: (2020)

Roswell Park, A. M., M. D.
por: Valentine, Ferd. C.
Publicado: (1893)

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
por: Krammer, Florian, et al.
Publicado: (2021)

Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers
por: Yoon, Sarang K., et al.
Publicado: (2022)

Reply to Noel-Savina and collaborators: D(M) and V(C) impairment after COVID-19
por: Gille, Thomas, et al.
Publicado: (2023)

Correspondence on Body Weight, Anti-SARS-CoV-2 Antibody and mRNA Vaccination
por: Sookaromdee, Pathum, et al.
Publicado: (2023)

Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab
por: Flores-Gonzalez, Ramon E, et al.
Publicado: (2021)

The A. M. D.
Publicado: (1882)

Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2
por: Blumenthal, Kimberly G., et al.
Publicado: (2021)

Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination
por: Frey, Sarah, et al.
Publicado: (2021)

Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination
por: Normark, Johan, et al.
Publicado: (2021)

Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose
por: Kuhlmann, Constanze, et al.
Publicado: (2022)

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
por: Pajon, Rolando, et al.
Publicado: (2022)

Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

M.D. and M.S., Bombay
por: Khambatta, Shirin
Publicado: (1950)

Aphasia seven days after second dose of an mRNA-based SARS-CoV-2 vaccine
por: Finsterer, Josef, et al.
Publicado: (2021)

Incident SARS-CoV-2 Infection among mRNA-Vaccinated and Unvaccinated Nursing Home Residents
por: White, Elizabeth M., et al.
Publicado: (2021)

Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination
por: Shen, Xiaoying, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron BA.1, BA.4, and BA.5 by primary ChAdOx1 nCoV-19, mRNA-1273, MVC-COV1901 and booster mRNA-1273 vaccination
por: Liu, Yuag-Meng, et al.
Publicado: (2022)

SARS-CoV-2 mRNA Vaccine Antibody Response in Patients with Asthma Receiving Biologic Therapy: A Real-World Analysis
por: Liao, Shu-Yi, et al.
Publicado: (2022)

SARS-CoV-2-specific IgM screening has low sensitivity for identifying potentially infectious travellers
por: Hasan, Tasnim, et al.
Publicado: (2021)

Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1
por: Uraki, Ryuta, et al.
Publicado: (2023)

Bivalent mRNA vaccine-elicited SARS-CoV-2 specific T cells recognise the omicron XBB sublineage
por: Traut, Caroline C, et al.
Publicado: (2023)

A. F. A. King, M. D.
por: King, A. F. A.
Publicado: (1890)

The B. M. A. Meeting, 1907
por: Birdwood, G. T.
Publicado: (1907)

Gailbraith A. Irvine, M.D.
por: Parker, T. F.
Publicado: (1867)

Dichotomy between the humoral and cellular responses elicited by mRNA and adenoviral vector vaccines against SARS-CoV-2
por: Ukey, Rahul, et al.
Publicado: (2022)

SARS-CoV-2 IgM testing for travellers: a private pathology perspective from New South Wales and the Australian Capital Territory, Australia
por: Wehrhahn, Michael C., et al.
Publicado: (2022)

The “M. D. S.”
por: Stockton, C. S.
Publicado: (1884)

A Manual for Junior I.M.S. Officers
Publicado: (1906)

A Reply to Dr. J. M. Thomas
por: Johnson, C. Evans
Publicado: (1893)

Cannot write session to /tmp/vufind_sessions/sess_23odb0410mserskri281prbf7m